MinichMacGregor Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

MinichMacGregor Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-40	Closed	-$5K	–	460
2018 Q3	$5K	Hold	40	–	–	﹤0.01%	395
2018 Q2	$5K	Hold	40	–	–	﹤0.01%	390
2018 Q1	$2K	Hold	40	–	–	﹤0.01%	434
2017 Q4	$2K	Hold	40	–	–	﹤0.01%	425
2017 Q3	$1K	Hold	40	–	–	﹤0.01%	450
2017 Q2	$1K	Hold	40	–	–	﹤0.01%	446
2017 Q1	$1K	Hold	40	–	–	﹤0.01%	434
2016 Q4	$1K	Hold	40	–	–	﹤0.01%	435
2016 Q3	$2K	Hold	40	–	–	﹤0.01%	384
2016 Q2	$0	Hold	40	–	–	﹤0.01%	467
2016 Q1	$0	Buy	+40	New	+$699	﹤0.01%	481

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

MinichMacGregor Wealth Management's SRPT Position: Q4 2018 in Review

MinichMacGregor Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 40 shares — an estimated $5K sold.

MinichMacGregor Wealth Management first reported a position in SRPT in Q1 2016 and held it in 11 quarters. The position peaked at $5K in Q3 2018. 335 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

MinichMacGregor Wealth Management reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
MinichMacGregor Wealth Management sold 40 Sarepta Therapeutics shares in Q4 2018, an estimated $5K.
MinichMacGregor Wealth Management first reported a position in Sarepta Therapeutics in Q1 2016 and held it in 11 quarters.
MinichMacGregor Wealth Management's Sarepta Therapeutics position peaked at $5K in Q3 2018.
335 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on MinichMacGregor Wealth Management's 13F filing for Q4 2018, filed 17 Jan 2019.